Rapid gains in genetics and genomics pose both great opportunities and challenges for the contemporary physician. The developmental goals of this K24 are intended to train and mentor patient-oriented physician scientists to conduct innovative research that will transform molecular genetics into molecular medicine. The applicant is a mid-career clinician-scientist whose investigational program focuses on applications of genomic science to the management of hereditary melanoma patients. The candidate is widely recognized for his contributions in the genetics of melanoma predisposition and progression. He founded and directs a vibrant Melanoma Genetics Program at the Massachusetts General Hospital (MGH), established a rich Hereditary Melanoma Registry at Harvard with over 250 melanoma families from throughout the world and leads both the Skin Cancer Genetics Laboratory in the Wellman Center for Photomedicine and the MGH Melanoma and Pigmented Lesion Center- a clinical unit dedicated to the care of melanoma patients;this multidisciplinary infrastructure provides unique opportunities to bring basic discoveries to the bedside. The applicant has mentored many medical students, specialty and subspecialty trainees and postdoctoral fellows in the proper conduct of patient-oriented molecular research. The mentorship plan includes a set of core training objectives: (1) to develop facility in skills required for academic success including the ability to execute the fundamentals of sound science, to write grants and manuscripts with coherence and cogency and to deliver a concise and convincing presentation, (2) to critically evaluate science for design and interpretation, (3) to effectively frame the scientific method from techniques to experiments to projects and finally to programs and (4) to mature within the context of a scientific community. These will be achieved through the execution of 4 broad scientific Aims: (1) create a robust model (termed MelaPRO) to estimate CDKN2A/CDK4 mutation carrier probability, (2) identify coding variants in RB-pathway genes in high-risk families lacking CDKN2A/CDK4 alterations (3) develop a flexible, accurate, high-throughput platform to assess CDKN2A/CDK4/MC1R genotypes and (4) devise novel functional assays for patient-derived variants in the melanocortin-1-receptor (MC1R) gene. Through the proposed K24 mid-career development award, the applicant will be able to develop several tangible products for the melanoma patient, to expand his own knowledge of important emerging area of variomics and, most importantly, to find the necessary time to mentor trainees and junior faculty and sustain a productive research laboratory.

Public Health Relevance

The scientific momentum ignited by the Human Genome Project has created unprecedented opportunities and challenges for medicine. In cutaneous melanoma, as in many other fields, an enlarging gulf divides the molecular scientist at the benchside and the clinician/researcher at the bedside. This K24 application is aimed at mentoring and training the next generation of patient-oriented physician-scientists to bridge this gap and to bring genetic discoveries to individuals and families affected by melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24CA149202-03
Application #
8249114
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
2010-05-01
Project End
2015-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
3
Fiscal Year
2012
Total Cost
$201,771
Indirect Cost
$14,946
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Redmond, Robert W; Rajadurai, Anpuchchelvi; Udayakumar, Durga et al. (2014) Melanocytes are selectively vulnerable to UVA-mediated bystander oxidative signaling. J Invest Dermatol 134:1083-90
Hawryluk, Elena B; Tsao, Hensin (2014) Melanoma: clinical features and genomic insights. Cold Spring Harb Perspect Med 4:a015388
Marzuka-Alcala, Alexander; Gabree, Michele Jacobs; Tsao, Hensin (2014) Melanoma susceptibility genes and risk assessment. Methods Mol Biol 1102:381-93
Chen, Steven T; Geller, Alan C; Tsao, Hensin (2013) Update on the Epidemiology of Melanoma. Curr Dermatol Rep 2:24-34
Puntervoll, Hanne Eknes; Yang, Xiaohong R; Vetti, Hildegunn Høberg et al. (2013) Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 50:264-70
Ji, Zhenyu; Kumar, Raj; Taylor, Michael et al. (2013) Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res 19:4383-91
Chen, Yiyin Erin; Tsao, Hensin (2013) The skin microbiome: current perspectives and future challenges. J Am Acad Dermatol 69:143-55
Njauw, Ching-Ni Jenny; Kim, Ivana; Piris, Adriano et al. (2012) Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 7:e35295
Ji, Zhenyu; Flaherty, Keith T; Tsao, Hensin (2012) Targeting the RAS pathway in melanoma. Trends Mol Med 18:27-35
Nikolaou, Vasiliki A; Stratigos, Alexander J; Flaherty, Keith T et al. (2012) Melanoma: new insights and new therapies. J Invest Dermatol 132:854-63

Showing the most recent 10 out of 18 publications